Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Pyrimidines"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 41-60 z 23614
Tytuł:
Glycogen Synthase Kinase-3 Inhibition by CHIR99021 Promotes Alveolar Epithelial Cell Proliferation and Lung Regeneration in the Lipopolysaccharide-Induced Acute Lung Injury Mouse Model.
Autorzy:
Fernandes R; Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Campus Gualtar, 4710-057 Braga, Portugal.; ICVS/3B's-PT Government Associate Laboratory, 4806-909 Braga, Portugal.
Barbosa-Matos C; Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Campus Gualtar, 4710-057 Braga, Portugal.; ICVS/3B's-PT Government Associate Laboratory, 4806-909 Braga, Portugal.
Borges-Pereira C; Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Campus Gualtar, 4710-057 Braga, Portugal.; ICVS/3B's-PT Government Associate Laboratory, 4806-909 Braga, Portugal.
Carvalho ALRT; Department of Internal Medicine, São João Universitary Hospital Center, 4200-319 Porto, Portugal.; Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal.
Costa S; Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Campus Gualtar, 4710-057 Braga, Portugal.; ICVS/3B's-PT Government Associate Laboratory, 4806-909 Braga, Portugal.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2024 Jan 20; Vol. 25 (2). Date of Electronic Publication: 2024 Jan 20.
Typ publikacji:
Journal Article
MeSH Terms:
Alveolar Epithelial Cells*
Acute Lung Injury*/chemically induced
Acute Lung Injury*/pathology
Pyridines*
Pyrimidines*
Animals ; Mice ; Lipopolysaccharides/pharmacology ; Glycogen Synthase Kinase 3 ; Lung/pathology ; Cell Proliferation
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Combination of Osimertinib and Olaparib Therapy to Treat Non-Small Cell Lung Cancer and High-Grade Serous Ovarian Carcinoma: A Case Report.
Autorzy:
Lin J; Schulich School of Medicine & Dentistry, Western University, London, ON N6A 3K7, Canada.
Welch S; Division of Medical Oncology, Department of Oncology, Western University, London, ON N6A 3K7, Canada.
Sanatani M; Division of Medical Oncology, Department of Oncology, Western University, London, ON N6A 3K7, Canada.
Ramadan S; Postgraduate Medical Education, Department of Oncology, Western University, London, ON N6A 3K7, Canada.
Pokaż więcej
Źródło:
Current oncology (Toronto, Ont.) [Curr Oncol] 2024 Jan 19; Vol. 31 (1), pp. 558-565. Date of Electronic Publication: 2024 Jan 19.
Typ publikacji:
Case Reports
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/genetics
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Ovarian Neoplasms*/drug therapy
Ovarian Neoplasms*/genetics
Ovarian Neoplasms*/pathology
Phthalazines*
Piperazines*
Acrylamides*
Aniline Compounds*
Indoles*
Pyrimidines*
Female ; Humans ; Aged ; Carcinoma, Ovarian Epithelial
Raport
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
A Multicenter, Randomized, Open-Label Study to Compare the Effects of Gemigliptin Add-on or Escalation of Metformin Dose on Glycemic Control and Safety in Patients with Inadequately Controlled Type 2 Diabetes Mellitus Treated with Metformin and SGLT-2 Inhibitors (SO GOOD Study).
Autorzy:
Kim HJ; Department of Endocrinology & Metabolism, Ajou University School of Medicine, Suwon, Republic of Korea.
Noh JH; Division of Endocrinology and Metabolism, Department of Medicine, Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Republic of Korea.
Moon MK; Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Republic of Korea.
Choi SH; Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.
Ko SH; Division of Endocrinology and Metabolism, Department of Internal Medicine, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Rhee EJ; Department of Endocrinology and Metabolism, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Hur KY; Division of Endocrinology and Metabolism, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Jeong IK; Division of Endocrinology and Metabolism, Department of Internal Medicine, Kyung Hee University Hospital at Gangdong, Kyung Hee University School of Medicine, Seoul, Republic of Korea.
Pokaż więcej
Źródło:
Journal of diabetes research [J Diabetes Res] 2024 Jan 05; Vol. 2024, pp. 8915591. Date of Electronic Publication: 2024 Jan 05 (Print Publication: 2024).
Typ publikacji:
Randomized Controlled Trial; Multicenter Study; Journal Article
MeSH Terms:
Diabetes Mellitus, Type 2*/drug therapy
Metformin*/administration & dosage
Piperidones*
Pyrimidines*
Sodium-Glucose Transporter 2 Inhibitors*/therapeutic use
Humans ; Blood Glucose ; Double-Blind Method ; Drug Therapy, Combination ; Glycated Hemoglobin ; Glycemic Control ; Hypoglycemic Agents/administration & dosage ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Short-term autophagy inhibition by autophinib or SAR405 does not alter the effect of cisplatin on ATP production in prostate cancer cells.
Autorzy:
Kratochvilova M
Stepka P
Raudenska M
Balvan J
Richtera L
Cernei N
Skopalova DS
Zitka O
Filipensky P
Babula P
Masarik M
Pokaż więcej
Źródło:
Bratislavske lekarske listy [Bratisl Lek Listy] 2024; Vol. 124 (2), pp. 84-91.
Typ publikacji:
Journal Article
MeSH Terms:
Cisplatin*/pharmacology
Prostatic Neoplasms*/drug therapy
Prostatic Neoplasms*/pathology
Pyrazoles*
Pyridines*
Pyrimidines*
Pyrimidinones*
Male ; Humans ; Autophagy ; Cell Line, Tumor ; Amino Acids/pharmacology ; Amino Acids/metabolism ; Adenosine Triphosphate/pharmacology ; Arginine
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
First-Line Alectinib vs. Brigatinib in Advanced Non-Small Cell Lung Cancer with ALK Rearrangement: Real-World Data.
Autorzy:
Jeon Y; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Park S; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Jung HA; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Sun JM; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Lee SH; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Ahn JS; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Ahn MJ; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Pokaż więcej
Źródło:
Cancer research and treatment [Cancer Res Treat] 2024 Jan; Vol. 56 (1), pp. 61-69. Date of Electronic Publication: 2023 Jul 14.
Typ publikacji:
Observational Study; Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/genetics
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Carbazoles*
Organophosphorus Compounds*
Pyrimidines*
Humans ; Piperidines/adverse effects ; Protein Kinase Inhibitors/adverse effects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Efficacy and safety of topical ruxolitinib cream for the treatment of vitiligo: A systematic review and meta-analysis of randomized controlled trials.
Autorzy:
Ehsan M; Department of Dermatology, King Edward Medical University, Lahore, Pakistan.; Department of Medicine, King Edward Medical University, Lahore, Pakistan.
Rehman AU; Department of Dermatology, King Edward Medical University, Lahore, Pakistan.; Department of Medicine, King Edward Medical University, Lahore, Pakistan.
Ayyan M; Department of Medicine, King Edward Medical University, Lahore, Pakistan.
Cheema HA; Department of Medicine, King Edward Medical University, Lahore, Pakistan.
Ahmad TZ; Department of Medicine, King Edward Medical University, Lahore, Pakistan.
Mustafa B; Department of Medicine, King Edward Medical University, Lahore, Pakistan.
Shahid A; Department of Medicine, King Edward Medical University, Lahore, Pakistan.
Khedro T; Department of Internal Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland.
Ismail H; Department of Internal Medicine, Limerick University Hospital, Limerick, Ireland.
Nashwan AJ; Hamad Medical Corporation, Doha, Qatar.
Pokaż więcej
Źródło:
Journal of cosmetic dermatology [J Cosmet Dermatol] 2024 Jan; Vol. 23 (1), pp. 350-353. Date of Electronic Publication: 2023 Jul 05.
Typ publikacji:
Meta-Analysis; Systematic Review; Letter
MeSH Terms:
Nitriles*/adverse effects
Pyrimidines*/adverse effects
Vitiligo*/drug therapy
Pyrazoles*/adverse effects
Humans ; Randomized Controlled Trials as Topic ; Treatment Outcome
Raport
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Lazertinib versus Gefitinib as First-Line Treatment for EGFR-mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset.
Autorzy:
Lee KH; Division of Medical Oncology, Department of Medicine, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, Korea.
Cho BC; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.
Ahn MJ; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Lee YG; Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.
Lee Y; Center for Lung Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Korea.
Lee JS; Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
Kim JH; CHA Bundang Medical Center, CHA University, Seongnam, Korea.
Min YJ; Division of Hematology and Oncology, Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.
Lee GW; Division of Hemato-Oncology, Department of Internal Medicine, Gyeongsang National University Hospital, Gyeongsang National University, College of Medicine, Jinju, Korea.
Lee SS; Inje University Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea.
Lee KH; Division of Hematology/Oncology, Department of Internal Medicine, Yeungnam University Medical Center, Daegu, Korea.
Ko YH; Department of Internal Medicine, Eunpyeong St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Shim BY; Division of Medical Oncology, Department of Internal Medicine, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Suwon, Korea.
Kim SW; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Shin SW; Division of Oncology/Hematology, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea.
Choi JH; Department of Hematology-Oncology, Ajou University School of Medicine, Suwon, Korea.
Kim DW; Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
Cho EK; Division of Oncology, Department of Internal Medicine, Gil Medical Center, Gachon University College of Medicine, Incheon, Korea.
Park KU; Division of Hematology/Oncology, Department of Internal Medicine, Keimyung University Dongsan Hospital, Daegu, Korea.
Kim JS; Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Korea.
Chun SH; Division of Medical Oncology, Department of Internal Medicine, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Wang J; Yuhan Corporation, Seoul, Korea.
Choi S; Yuhan Corporation, Seoul, Korea.
Kang JH; Division of Medical Oncology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Pokaż więcej
Źródło:
Cancer research and treatment [Cancer Res Treat] 2024 Jan; Vol. 56 (1), pp. 48-60. Date of Electronic Publication: 2023 Jun 27.
Typ publikacji:
Randomized Controlled Trial; Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/genetics
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Morpholines*
Pyrazoles*
Pyrimidines*
Humans ; Gefitinib/therapeutic use ; Quinazolines ; ErbB Receptors/genetics ; ErbB Receptors/metabolism ; Republic of Korea ; Mutation ; Protein Kinase Inhibitors/adverse effects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Applied physiologically-based pharmacokinetic modeling to assess uridine diphosphate-glucuronosyltransferase-mediated drug-drug interactions for Vericiguat.
Autorzy:
Frechen S; Pharmacometrics/Modeling and Simulation, Research and Development, Pharmaceuticals, Bayer AG, Leverkusen, Germany.
Ince I; Pharmacometrics/Modeling and Simulation, Research and Development, Pharmaceuticals, Bayer AG, Leverkusen, Germany.
Dallmann A; Pharmacometrics/Modeling and Simulation, Research and Development, Pharmaceuticals, Bayer AG, Leverkusen, Germany.
Gerisch M; DMPK, Research and Development, Pharmaceuticals, Bayer AG, Leverkusen, Germany.
Jungmann NA; DMPK, Research and Development, Pharmaceuticals, Bayer AG, Leverkusen, Germany.
Becker C; Clinical Pharmacology, Research and Development, Pharmaceuticals, Bayer AG, Leverkusen, Germany.
Lobmeyer M; Clinical Pharmacology, Research and Development, Pharmaceuticals, Bayer AG, Leverkusen, Germany.
Trujillo ME; Merck & Co., Inc., Rahway, New Jersey, USA.
Xu S; Merck & Co., Inc., Rahway, New Jersey, USA.
Burghaus R; Pharmacometrics/Modeling and Simulation, Research and Development, Pharmaceuticals, Bayer AG, Leverkusen, Germany.
Meyer M; Pharmacometrics/Modeling and Simulation, Research and Development, Pharmaceuticals, Bayer AG, Leverkusen, Germany.
Pokaż więcej
Źródło:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2024 Jan; Vol. 13 (1), pp. 79-92. Date of Electronic Publication: 2023 Oct 12.
Typ publikacji:
Journal Article
MeSH Terms:
Mefenamic Acid*
Glucuronosyltransferase*/metabolism
Heterocyclic Compounds, 2-Ring*
Pyrimidines*
Humans ; Atazanavir Sulfate ; Drug Interactions
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
BAY-3827 and SBI-0206965: Potent AMPK Inhibitors That Paradoxically Increase Thr172 Phosphorylation.
Autorzy:
Hawley SA; Division of Cell Signalling & Immunology, School of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, UK.
Russell FM; Division of Cell Signalling & Immunology, School of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, UK.
Ross FA; Division of Cell Signalling & Immunology, School of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, UK.
Hardie DG; Division of Cell Signalling & Immunology, School of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, UK.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Dec 29; Vol. 25 (1). Date of Electronic Publication: 2023 Dec 29.
Typ publikacji:
Journal Article
MeSH Terms:
Diabetes Mellitus, Type 2*
Lung Neoplasms*
Benzamides*
Pyrimidines*
Humans ; Phosphorylation ; Protein Kinase Inhibitors/pharmacology ; AMP-Activated Protein Kinases
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Overcoming the imatinib-resistant BCR-ABL mutants with new ureidobenzothiazole chemotypes endowed with potent and broad-spectrum anticancer activity.
Autorzy:
El-Damasy AK; Center for Brain Technology, Brain Science Institute, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea.; Department of Medicinal Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt.
Jin H; Center for Brain Technology, Brain Science Institute, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea.
Park JW; Center for Supercomputing Applications, Div. of National Supercomputing R&D, Korea Institute of Science and Technology Information, Daejeon, Republic of Korea.
Kim HJ; Center for Brain Technology, Brain Science Institute, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea.
Khojah H; Department of Pharmacognosy, College of Pharmacy, Jouf University, Sakaka, Saudi Arabia.
Seo SH; Center for Brain Disorders, Brain Science Institute, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea.
Lee JH; Center for Brain Technology, Brain Science Institute, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea.
Bang EK; Center for Brain Technology, Brain Science Institute, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea.
Keum G; Center for Brain Technology, Brain Science Institute, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea.; Division of Bio-Medical Science & Technology, KIST School, Korea University of Science and Technology (UST), Seoul, Republic of Korea.
Pokaż więcej
Źródło:
Journal of enzyme inhibition and medicinal chemistry [J Enzyme Inhib Med Chem] 2023 Dec; Vol. 38 (1), pp. 2189097.
Typ publikacji:
Journal Article
MeSH Terms:
Fusion Proteins, bcr-abl*/genetics
Pyrimidines*/pharmacology
Imatinib Mesylate/pharmacology ; Piperazines/pharmacology ; Benzamides/pharmacology ; Apoptosis
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Dual inhibition of CDK12 and CDK13 uncovers actionable vulnerabilities in patient-derived ovarian cancer organoids.
Autorzy:
Cesari E; Department of Neuroscience, Section of Human Anatomy, Catholic University of the Sacred Heart, 00168, Rome, Italy.; GSTeP Organoids Research Core Facility, IRCCS Fondazione Policlinico A. Gemelli, 00168, Rome, Italy.
Ciucci A; GSTeP Organoids Research Core Facility, IRCCS Fondazione Policlinico A. Gemelli, 00168, Rome, Italy.; Department of Woman and Child Health and Public Health, Catholic University of the Sacred Heart, 00168, Rome, Italy.
Pieraccioli M; Department of Neuroscience, Section of Human Anatomy, Catholic University of the Sacred Heart, 00168, Rome, Italy.; GSTeP Organoids Research Core Facility, IRCCS Fondazione Policlinico A. Gemelli, 00168, Rome, Italy.
Caggiano C; Department of Neuroscience, Section of Human Anatomy, Catholic University of the Sacred Heart, 00168, Rome, Italy.; GSTeP Organoids Research Core Facility, IRCCS Fondazione Policlinico A. Gemelli, 00168, Rome, Italy.
Nero C; Department of Woman and Child Health and Public Health, Catholic University of the Sacred Heart, 00168, Rome, Italy.; Department of Woman and Child Health and Public Health, Gynecologic Oncology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo Francesco Vito 1, 00168, Rome, Italy.
Bonvissuto D; Department of Neuroscience, Section of Human Anatomy, Catholic University of the Sacred Heart, 00168, Rome, Italy.
Sillano F; Department of Woman and Child Health and Public Health, Catholic University of the Sacred Heart, 00168, Rome, Italy.
Buttarelli M; Department of Woman and Child Health and Public Health, Catholic University of the Sacred Heart, 00168, Rome, Italy.; Unit of Translational Medicine for Woman and Child Health, IRCCS Fondazione Policlinico Universitario A. Gemelli, 00168, Rome, Italy.
Piermattei A; Department of Woman and Child Health and Public Health, Catholic University of the Sacred Heart, 00168, Rome, Italy.
Loverro M; Department of Woman and Child Health and Public Health, Catholic University of the Sacred Heart, 00168, Rome, Italy.; Department of Woman and Child Health and Public Health, Gynecologic Oncology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo Francesco Vito 1, 00168, Rome, Italy.
Camarda F; Department of Woman and Child Health and Public Health, Catholic University of the Sacred Heart, 00168, Rome, Italy.; Department of Woman and Child Health and Public Health, Gynecologic Oncology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo Francesco Vito 1, 00168, Rome, Italy.
Greco V; Department of Diagnostic and Laboratory Medicine, Unity of Chemistry, Biochemistry and Clinical Molecular Biology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.; Department of Basic Biotechnological Sciences, Intensive Care and Perioperative Clinics Research, Catholic University of the Sacred Heart, Università Cattolica del Sacro Cuore, Rome, Italy.
De Bonis M; Department of Basic Biotechnological Sciences, Intensive Care and Perioperative Clinics Research, Catholic University of the Sacred Heart, Università Cattolica del Sacro Cuore, Rome, Italy.
Minucci A; Department of Basic Biotechnological Sciences, Intensive Care and Perioperative Clinics Research, Catholic University of the Sacred Heart, Università Cattolica del Sacro Cuore, Rome, Italy.
Gallo D; Department of Woman and Child Health and Public Health, Catholic University of the Sacred Heart, 00168, Rome, Italy.; Unit of Translational Medicine for Woman and Child Health, IRCCS Fondazione Policlinico Universitario A. Gemelli, 00168, Rome, Italy.
Urbani A; Department of Diagnostic and Laboratory Medicine, Unity of Chemistry, Biochemistry and Clinical Molecular Biology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.; Department of Basic Biotechnological Sciences, Intensive Care and Perioperative Clinics Research, Catholic University of the Sacred Heart, Università Cattolica del Sacro Cuore, Rome, Italy.
Vizzielli G; Department of Medical Area (DAME), University of Udine, Udine, Italy.; Clinic of Obstetrics and Gynecology, 'Santa Maria Della Misericordia' University Hospital, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy.
Scambia G; Department of Woman and Child Health and Public Health, Catholic University of the Sacred Heart, 00168, Rome, Italy. .; Department of Woman and Child Health and Public Health, Gynecologic Oncology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo Francesco Vito 1, 00168, Rome, Italy. .
Sette C; Department of Neuroscience, Section of Human Anatomy, Catholic University of the Sacred Heart, 00168, Rome, Italy. .; GSTeP Organoids Research Core Facility, IRCCS Fondazione Policlinico A. Gemelli, 00168, Rome, Italy. .
Pokaż więcej
Źródło:
Journal of experimental & clinical cancer research : CR [J Exp Clin Cancer Res] 2023 May 18; Vol. 42 (1), pp. 126. Date of Electronic Publication: 2023 May 18.
Typ publikacji:
Journal Article
MeSH Terms:
Ovarian Neoplasms*/drug therapy
Ovarian Neoplasms*/genetics
Pyrimidines*/pharmacology
Pyrimidines*/therapeutic use
Female ; Humans ; Anilides/pharmacology ; Anilides/therapeutic use ; CDC2 Protein Kinase/metabolism ; Cyclin-Dependent Kinases/genetics ; Organoids/metabolism
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The host-directed therapeutic imatinib mesylate accelerates immune responses to Mycobacterium marinum infection and limits pathology associated with granulomas.
Autorzy:
Cleverley TL; Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, United States of America.; Immunology and Molecular Pathogenesis Graduate Program, Emory University School of Medicine, Atlanta, Georgia, United States of America.
Peddineni S; Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, United States of America.
Guarner J; Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, United States of America.
Cingolani F; Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, United States of America.
Garcia PK; Immunology and Molecular Pathogenesis Graduate Program, Emory University School of Medicine, Atlanta, Georgia, United States of America.
Koehler H; Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, United States of America.
Mocarski ES; Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia, United States of America.
Kalman D; Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, United States of America.
Pokaż więcej
Źródło:
PLoS pathogens [PLoS Pathog] 2023 May 18; Vol. 19 (5), pp. e1011387. Date of Electronic Publication: 2023 May 18 (Print Publication: 2023).
Typ publikacji:
Journal Article
MeSH Terms:
Pyrimidines*/pharmacology
Piperazines*/pharmacology
Humans ; Animals ; Mice ; Imatinib Mesylate/pharmacology ; Benzamides ; Anti-Bacterial Agents/therapeutic use ; Granuloma/drug therapy
SCR Disease Name:
Infection with Mycobacterium marinum
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Three Component One-Pot Synthesis and Antiproliferative Activity of New [1,2,4]Triazolo[4,3- a ]pyrimidines.
Autorzy:
Ben Hassen M; Laboratory of Applied Chemistry: Heterocycles, Lipids, and Polymers, Faculty of Sciences of Sfax, University of Sfax, Sfax 3000, Tunisia.
Msalbi D; Laboratory of Molecular and Cellular Screening Processes, Centre of Biotechnology of Sfax, Sfax 3018, Tunisia.
Jismy B; Laboratory of Physico-Chemistry of Materials and Electrolytes for Energy (PCM2E), Faculty of Science and Technology, University of Tours, 37200 Tours, France.
Elghali F; Laboratory of Molecular and Cellular Screening Processes, Centre of Biotechnology of Sfax, Sfax 3018, Tunisia.
Aifa S; Laboratory of Molecular and Cellular Screening Processes, Centre of Biotechnology of Sfax, Sfax 3018, Tunisia.
Allouchi H; Faculty of Pharmacy, University of Tours, 37200 Tours, France.
Abarbri M; Laboratory of Physico-Chemistry of Materials and Electrolytes for Energy (PCM2E), Faculty of Science and Technology, University of Tours, 37200 Tours, France.
Chabchoub F; Laboratory of Applied Chemistry: Heterocycles, Lipids, and Polymers, Faculty of Sciences of Sfax, University of Sfax, Sfax 3000, Tunisia.
Pokaż więcej
Źródło:
Molecules (Basel, Switzerland) [Molecules] 2023 May 05; Vol. 28 (9). Date of Electronic Publication: 2023 May 05.
Typ publikacji:
Journal Article
MeSH Terms:
Pyrimidines*/chemistry
Antineoplastic Agents*/chemistry
Humans ; Cisplatin/pharmacology ; MCF-7 Cells ; Magnetic Resonance Spectroscopy ; Drug Screening Assays, Antitumor ; Structure-Activity Relationship ; Cell Proliferation ; Cell Line, Tumor ; Molecular Structure
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
FIGHT-102: A phase 1 study of pemigatinib in Japanese patients with advanced malignancies.
Autorzy:
Fujiwara Y; National Cancer Center Hospital, Tokyo, Japan.; Aichi Cancer Center, Nagoya, Japan.
Kuboki Y; National Cancer Central Hospital East, Chiba, Japan.
Furukawa M; Kyushu Cancer Center, Fukuoka, Japan.
Mizuno N; Aichi Cancer Center, Nagoya, Japan.
Hara H; Saitama Cancer Center, Saitama, Japan.
Ioka T; Department of Oncology Center, Yamaguchi University Hospital, Ube, Japan.
Ueno M; Kanagawa Cancer Center, Yokohama, Japan.
Takahashi Y; Hokkaido Cancer Center, Sapporo, Japan.
Takahashi S; Cancer Institute Hospital of JFCR, Tokyo, Japan.
Takeuchi S; Kanazawa University Hospital, Kanazawa, Japan.
Lihou C; Incyte Corporation, Wilmington, Delaware, USA.
Ji T; Incyte Corporation, Wilmington, Delaware, USA.
Tian C; Incyte Corporation, Wilmington, Delaware, USA.
Shimizu T; National Cancer Center Hospital, Tokyo, Japan.; Wakayama Medical University, Wakayama, Japan.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2023 May; Vol. 12 (9), pp. 10597-10611. Date of Electronic Publication: 2023 Mar 31.
Typ publikacji:
Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Neoplasms*/drug therapy
Morpholines*/therapeutic use
Pyrimidines*/therapeutic use
Pyrroles*/therapeutic use
Adult ; Humans ; Young Adult ; East Asian People
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Synthesis and Antioxidant Activities of Novel Pyrimidine Acrylamides as Inhibitors of Lipoxygenase: Molecular Modeling and In Silico Physicochemical Studies.
Autorzy:
Saragatsis M; Laboratory of Pharmaceutical Chemistry, School of Pharmacy, Faculty of Health Sciences, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
Pontiki E; Laboratory of Pharmaceutical Chemistry, School of Pharmacy, Faculty of Health Sciences, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
Pokaż więcej
Źródło:
Molecules (Basel, Switzerland) [Molecules] 2024 Mar 07; Vol. 29 (6). Date of Electronic Publication: 2024 Mar 07.
Typ publikacji:
Journal Article
MeSH Terms:
Antioxidants*/chemistry
Acrylamides*
Molecular Docking Simulation ; Lipoxygenase/metabolism ; Anti-Inflammatory Agents/pharmacology ; Lipoxygenase Inhibitors/chemistry ; Amides/chemistry ; Pyrimidines/pharmacology ; Piperidines ; Structure-Activity Relationship ; Molecular Structure
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Designing Potent Anti-Cancer Agents: Synthesis and Molecular Docking Studies of Thieno[2,3- d ][1,2,4]triazolo[1,5- a ]pyrimidine Derivatives.
Autorzy:
Elsenbawy ESM; Department of Chemistry, Faculty of Science, Menofia University, Shbien El-Kom 32511, Egypt.
Alshehri ZS; Department of Medical Laboratories, College of Applied Medical Sciences, Shaqra University, Dawadmi 19257, Saudi Arabia.
Babteen NA; Department of Biochemistry, College of Sciences, University of Jeddah, Jeddah 21577, Saudi Arabia.
Abdel-Rahman AA; Department of Chemistry, Faculty of Science, Menofia University, Shbien El-Kom 32511, Egypt.
El-Manawaty MA; Department of Pharmacognosy, Pharmaceutical Science Division, National Research Centre, Cairo 12622, Egypt.
Nossier ES; Department of Pharmaceutical Medicinal Chemistry and Drug Design, Faculty of Pharmacy (Girls), Al-Azhar University, Cairo 11754, Egypt.
Arafa RK; Drug Design and Discovery Laboratory, Biomedical Sciences Program, University of Science and Technology, Zewail City of Science and Technology, Ahmed Zewail Road, October Gardens, Cairo 12578, Egypt.
Hassan NA; Synthetic Unit, Department of Photochemistry, Chemical Industries Research Institute, National Research Centre, Cairo 12622, Egypt.
Pokaż więcej
Źródło:
Molecules (Basel, Switzerland) [Molecules] 2024 Feb 29; Vol. 29 (5). Date of Electronic Publication: 2024 Feb 29.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Agents*/pharmacology
Humans ; Molecular Structure ; Structure-Activity Relationship ; Molecular Docking Simulation ; Pyrimidines/pharmacology ; Triazoles/pharmacology ; Drug Screening Assays, Antitumor ; Cell Proliferation ; Cell Line, Tumor ; Drug Design
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Current therapeutic landscape and resistance mechanisms to larotrectinib.
Autorzy:
Xie W; Department of Pediatric Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Xu J; Department of Pediatric Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Lu S; Department of Pediatric Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Zhang Y; Department of Pediatric Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.; Young Talents Program of Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Pokaż więcej
Źródło:
Cancer biology & medicine [Cancer Biol Med] 2024 Feb 05; Vol. 20 (12).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Neoplasms*/drug therapy
Humans ; Pyrazoles/pharmacology ; Pyrazoles/therapeutic use ; Pyrimidines/pharmacology ; Pyrimidines/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Pyrimidine Schiff Bases: Synthesis, Structural Characterization and Recent Studies on Biological Activities.
Autorzy:
Bryndal, Iwona (AUTHOR)
Stolarczyk, Marcin (AUTHOR)
Mikołajczyk, Aleksandra (AUTHOR)
Krupińska, Magdalena (AUTHOR)
Pyra, Anna (AUTHOR)
Mączyński, Marcin (AUTHOR)
Matera-Witkiewicz, Agnieszka (AUTHOR)
Pokaż więcej
Źródło:
International Journal of Molecular Sciences. Feb2024, Vol. 25 Issue 4, p2076. 27p.
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Design, Synthesis and Bioactivity of Novel Pyrimidine Sulfonate Esters Containing Thioether Moiety.
Autorzy:
Li C; Key Laboratory Breeding Base of Green Pesticide and Agricultural Bioengineering, Key Laboratory of Green Pesticide and Agricultural Bioengineering, Ministry of Education, Guizhou University, Guiyang 550025, China.
Liu Y; Key Laboratory Breeding Base of Green Pesticide and Agricultural Bioengineering, Key Laboratory of Green Pesticide and Agricultural Bioengineering, Ministry of Education, Guizhou University, Guiyang 550025, China.
Ren X; Key Laboratory Breeding Base of Green Pesticide and Agricultural Bioengineering, Key Laboratory of Green Pesticide and Agricultural Bioengineering, Ministry of Education, Guizhou University, Guiyang 550025, China.
Tan Y; Key Laboratory Breeding Base of Green Pesticide and Agricultural Bioengineering, Key Laboratory of Green Pesticide and Agricultural Bioengineering, Ministry of Education, Guizhou University, Guiyang 550025, China.
Jin L; Key Laboratory Breeding Base of Green Pesticide and Agricultural Bioengineering, Key Laboratory of Green Pesticide and Agricultural Bioengineering, Ministry of Education, Guizhou University, Guiyang 550025, China.
Zhou X; Key Laboratory Breeding Base of Green Pesticide and Agricultural Bioengineering, Key Laboratory of Green Pesticide and Agricultural Bioengineering, Ministry of Education, Guizhou University, Guiyang 550025, China.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Feb 28; Vol. 24 (5). Date of Electronic Publication: 2023 Feb 28.
Typ publikacji:
Journal Article
MeSH Terms:
Anti-Bacterial Agents*/chemical synthesis
Anti-Bacterial Agents*/chemistry
Anti-Bacterial Agents*/pharmacology
Esters*/chemical synthesis
Esters*/chemistry
Esters*/pharmacology
Pesticides*/chemical synthesis
Pesticides*/chemistry
Pesticides*/pharmacology
Pyrimidines*/chemical synthesis
Pyrimidines*/chemistry
Pyrimidines*/pharmacology
Sulfides*/chemical synthesis
Sulfides*/chemistry
Sulfides*/pharmacology
Alkanesulfonates ; Microbial Sensitivity Tests ; Oryza/microbiology ; Plant Diseases/microbiology ; Xanthomonas/drug effects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 41-60 z 23614

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies